{"id":390123,"date":"2020-12-29T00:00:00","date_gmt":"2020-12-29T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/exinid0002-2020-biopharma-hospital-treated-covid-19-executive-insights-multiple-geographies-2020\/"},"modified":"2026-04-21T05:24:44","modified_gmt":"2026-04-21T05:24:44","slug":"exinid0002-2020-biopharma-hospital-treated-covid-19-executive-insights-multiple-geographies-2020","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/exinid0002-2020-biopharma-hospital-treated-covid-19-executive-insights-multiple-geographies-2020\/","title":{"rendered":"Hospital-Treated COVID-19 | Executive Insights | Multiple Geographies | 2020"},"content":{"rendered":"<p>The treatment landscape for COVID-19 is rapidly evolving, as such, intense\u00a0research is focused on approaches designed to reduce viral load and\/or improve outcomes in hospitalized patients infected with SARS-CoV-2. Currently, Veklury (remdesivir) is the only approved drug for hospitalized COVID-19 patients in the United States; the agent holds a conditional marketing authorization in Europe and can be used under an exceptional approval pathway in Japan. The disease poses a high burden to the healthcare system, and presents a high unmet need. A myriad of drugs with diverse mechanisms of action are in clinical development for hospitalized COVID-19 patients. Should any of these pipeline candidates launch into the COVID-19 marketplace, it will transform the treatment landscape and help address the existing unmet need.Paste Abstract text here<\/p>\n","protected":false},"template":"","class_list":["post-390123","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-date-942"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390123","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390123\/revisions"}],"predecessor-version":[{"id":393248,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390123\/revisions\/393248"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390123"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}